Rhophylac ZLB Bioplasma AG, Switzerland - Treatment for Prevention of Rho(D) Sensitization
Rhophylac is a highly purified, plasma-derived product comprised of
Rho(D) Immune Globulin (Human) for IV or IM administration.
Rhophylac is primarily indicated for the prevention of hemolytic
disease of the fetus and newborn (HDN), and also indicated to
prevent Rho(D) sensitization after transfusion of Rh-positive blood
type to Rh-negative patient.
Posted: February 2004
Rhophylac (Rh0(D) immune globulin intravenous (human)) FDA Approval History